| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 5,590 | 4,690 | 2,700 | 6,600 | 17,940 |
| Sales Growth | +19.19% | +73.70% | -59.09% | -63.21% | unch |
| Net Income | -36,750 | -49,940 | -47,890 | -42,060 | -17,670 |
| Net Income Growth | +26.41% | -4.28% | -13.86% | -138.03% | +19.75% |
Oyster Point Pharma Inc (OYST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company's lead product candidate, OC-01, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Oyster Point Pharma Inc. is based in Princeton, New Jersey.
Fiscal Year End Date: 12/31